BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 9808489)

  • 1. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
    Kahan BD; Podbielski J; Napoli KL; Katz SM; Meier-Kriesche HU; Van Buren CT
    Transplantation; 1998 Oct; 66(8):1040-6. PubMed ID: 9808489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination.
    Machado PG; Felipe CR; Hanzawa NM; Park SI; Garcia R; Alfieri F; Franco M; Silva HT; Medina-Pestana JO
    Clin Transplant; 2004 Feb; 18(1):28-38. PubMed ID: 15108768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.
    Kahan BD; Julian BA; Pescovitz MD; Vanrenterghem Y; Neylan J
    Transplantation; 1999 Nov; 68(10):1526-32. PubMed ID: 10589950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
    Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
    Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection.
    Tsai MK; Chueh SC; Hu RH; Lee PH
    J Formos Med Assoc; 2003 Feb; 102(2):91-6. PubMed ID: 12709737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.
    MacDonald AS;
    Transplantation; 2001 Jan; 71(2):271-80. PubMed ID: 11213073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K
    Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.
    Kahan BD
    Lancet; 2000 Jul; 356(9225):194-202. PubMed ID: 10963197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection.
    Kahan BD; Kaplan B; Lorber MI; Winkler M; Cambon N; Boger RS
    Transplantation; 2001 May; 71(10):1400-6. PubMed ID: 11391226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
    Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
    Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Improved outcome with sirolimus-cyclosporine regimen in high-risk renal transplant recipients].
    Podder H; Forgács B; Csapó Z; Kahan B
    Orv Hetil; 2005 Jul; 146(31):1641-6. PubMed ID: 16158614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
    Zhu L; Ding T; Wang XX; Lin ZB; Chen G
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus rescue therapy for refractory rejection in renal transplantation.
    Hong JC; Kahan BD
    Transplantation; 2001 Jun; 71(11):1579-84. PubMed ID: 11435968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus improves the two-year outcome of renal allografts in African-American patients.
    Podder H; Podbielski J; Hussein I; Katz S; Van Buren C; Kahan BD
    Transpl Int; 2001 Jun; 14(3):135-42. PubMed ID: 11499902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety.
    Velosa JA; Larson TS; Gloor JM; Stegall MD
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S3-S10. PubMed ID: 11583938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study.
    Mühlbacher F; Neumayer HH; del Castillo D; Stefoni S; Zygmunt AJ; Budde K;
    Transpl Int; 2014 Feb; 27(2):176-86. PubMed ID: 24266855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
    Shihab FS; Cibrik D; Chan L; Kim YS; Carmellini M; Walker R; Zibari G; Pattison J; Cornu-Artis C; Wang Z; Tedesco-Silva H
    Clin Transplant; 2013; 27(2):217-26. PubMed ID: 23230975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function.
    Knight RJ; Kerman RH; Schoenberg L; Podder H; Van Buren CT; Katz S; Kahan BD
    Transplantation; 2004 Sep; 78(6):904-10. PubMed ID: 15385812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.